Local immunosuppression with budesonide after liver transplantation in the rat: A preliminary histomorphological analysis

Transplantation

Volumn 64, Issue 5, 1997, Pages 705-708

  Weber, Thomas ^a   Kalbhenn, Thilo ^a   Herrmann, Günter ^a   Hanisch, Ernst ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BUDESONIDE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CELL INFILTRATION; CONTROLLED STUDY; DOSE RESPONSE; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOSUPPRESSIVE TREATMENT; LIVER CLEARANCE; LIVER NECROSIS; LIVER TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; RAT;

ACID PHOSPHATASE; ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ALANINE TRANSAMINASE; ANIMALS; ANTI-INFLAMMATORY AGENTS; ASPARTATE AMINOTRANSFERASES; BUDESONIDE; GLUCOCORTICOIDS; GRAFT REJECTION; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MONOCYTES; PREGNENEDIONES; RATS; RATS, INBRED LEW; RATS, INBRED STRAINS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0030923589     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199709150-00007     Document Type: Article

References (25)

1. Medawar PB. The immunology of transplantation. Harvey Lect 1956-1957; 52: 144.
2. Ascher NL, Hoffmann R, Chen S, et al. Specific and nonspecific infiltration of sponge matrix allografts by specifically sensitized cytotoxic lymphocytes. Cell Immunol 1980; 52: 38.
3. Nemlander A, Soots A, von Willebrand E, et al. Redistribution of renal allograft responding leukocytes during rejection. J Exp Med 1982; 156: 1087.
4. Cramer DV. Cardiac transplantation: immune mechanism and alloantigens involved in cardiac rejection. CRC Crit Rev Immunol 1987; 7: 1.
5. Gruber SA. The case for local immunosuppression. Transplantation 1992; 54: 1.
6. Ruers TJM, Buurman WA, Daemen MJAP, van der Linden CJ, Koostra G. Local budesonide treatment of rat cardiac allografts results in effective immunosuppression without systemic immunological side effects. Transplant Proc 1990; 22: 1993.
7. Ruers TJM, Schutte B, van der Linden CJ, Buurman WA. Cellular proliferation at the site of organ allografts and the influence of immunosuppressive therapy. Transplantation 1990; 50: 568.
8. Stepkowski SM, Goto S, Ito T, et al. Prolongation of heterotopic heart allograft survival by local delivery of continuous low-dose cyclosporine therapy. Transplantation 1989; 47: 17.
9. Ko S, Nakajima Y, Kanehiro H, et al. The significance of local immunosuppression in canine liver transplantation. Transplantation 1994; 57: 1818.
10. Dowling RD, Zenati M, Burckart GJ, et al. Aerosolized cyclosporine as single-agent immunotherapy in canine lung allografts. Surgery 1990; 108: 198.
11. Edsbäcker S, Andersson P, Lindberg J, Paulson J, Ryrfeldt A, Thalen A. Liver metabolism of budesonide in rat, mouse, and man. Drug Metab Dispos 1987; 15: 403.
12. Chanoine P, Grenot C, Heidmann P, Junien JL. Pharmacokinetics of butixocort 21-propionate, budesonide, and beclomethasone dipropionate in the rat after intratracheal, intravenous and oral treatments. Drug Metab Dispos 1991; 19: 546.
13. Ryrfeldt A, Andersson P, Edsbäcker S, Tönnesen M, Davies D, Pauwels R. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Respir Dis 1982; 63 (suppl 122): 86.
14. Brattsand A, Thalen A, Roempke L, Källström L, Gruvstad E. Development of new glucocorticoids with a very high ratio between topical and systemic activities. Eur J Respir Dis 1982; 63 (suppl 122): 62.
15. Andersson P, Appelgren LE, Ryrfeldt A. Tissue distribution and fate of budesonide in the mouse. Acta Pharmacol Toxicol (Copenh) 1986; 59: 392.
16. Zimmermann FA, Knoll PP, Davies HS, Gokel JM, Schmid T. The fate of liver allografts in different rat strain combinations. Transplant Proc 1983; 15: 1272.
17. Kamada N, Calne RY. Orthotopic liver transplantation in the rat: technique using cuff for portal vein anastomosis and biliary drainage. Transplantation 1979; 28: 47.
18. Löfberg R, Ostergaard Thomsen O, Langholtz E, Schioler R, Danielsson A, Suhr O. Budesonide vs. prednisolone enema in active ulcerative colitis: a comparative eight week study. Gut 1993; 34 (suppl 1): 41.
19. Matzen P and the Danish Budesonide Group. Budesonide enema in ulcerative colitis: a randomized dose-response trial with prednisolone enema as a positive control. Scand J Gastroenterol 1991; 26: 1225.
20. Rutgeerts P, Löfberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994; 29: 842.
21. Caesar I, Gross V, Roth M, et al. Treatment of active Crohn's ileocolitis with oral pH-modified budesonide. Z Gastroenterol 1995; 33: 247.
22. Klintmalm GBG, Husberg BS, Starzl TE. The organ transplanted patient: immunological concepts and immunosuppression. In: Makowka L, ed. The handbook of transplantation management. Austin: R.G. Landes, 1991: 80.
23. Claman HN. Glucocorticosteroids. I. Antiinflammatory mechanism. Hosp Pract 1983; 7: 123.
24. Council on Scientific Affairs. Introduction to the management of immunosuppression. JAMA 1987; 257: 1781.
25. Ruers TJM, Buurman WA, van der Linden CJ, Koostra G. Local inhibition of major histocompatibility complex class II induction within the graft: an effective way to induce immunosuppression. Transplant Proc 1987; 19: 246.